Skip to main content

Lifeward Ltd.

corporate_fare Company Profile

Lifeward Ltd.

LFWD·NASDAQ·Industrial Applications And Services·CIK 0001607962

ReWalk is a medical device company that designs, develops, and commercializes solutions for physical rehabilitation and recovery. The company's initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices, referred to as SCI Products, for individuals with spinal cord injury. These robotic exoskeletons use patented tilt-sensor technology, an onboard computer, and motion sensors to power motorized legs, enabling individuals with paraplegia to stand and walk. In March 2023, ReWalk received 510(k) clearance from the U.S. FDA for the ReWalk Personal Exoskeleton with stair and curb functionality, allowing U.S. users to navigate stairs and curbs. This feature has been available in Europe since initial CE Clearance, supported by real-world data from 47 European users over seven years, involving over 18,000 stair steps. In March 2025, the company received 510(k) clearance for the ReWalk 7 Personal Exoskeleton device, a next-generation model. ReWalk has also expanded its product offerings beyond SCI Products, including the ReStore Exo-Suit device, which began commercialization in June 2019. The ReStore is a powered, lightweight soft exo-suit designed for the rehabilitation of individuals with lower limb disabilities due to stroke. Sales of the ReStore device in the European Union ceased in May 2024.

Lifeward Ltd. (NASDAQ:LFWD) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 47 items for LFWD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Shareholders to Vote on Highly Dilutive Financing and Oratech Acquisition, Resulting in 88% Dilution
  • Lifeward Ltd. Receives Nasdaq Delisting Extension After Failing to Meet Minimum Bid Price
  • Shareholders to Vote on Highly Dilutive Financing and Acquisition Critical for Company Survival
  • Shareholders to Vote on Highly Dilutive Oramed Acquisition Terms, Potential Change of Control
  • Lifeward Secures $47M Capital Infusion and Biotech Diversification via Highly Dilutive Oramed Partnership

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$22.03M
Net Income
-$19.91M
Diluted EPS
-$17.16
Op. Cash Flow
-$16.83M
Free Cash Flow
-$16.84M
Gross Profit
$8.43M
Operating Income
-$19.67M
Cash & Equivalents
$2.17M
Debt / Equity
0.00×
Net Margin
-90.4%
Shares Outstanding
1.52M sh
Source: 10-K · filed 2026-03-18 · accession 0001178913-26-001208
$2.8 -4.98% today
52-week range · as of 2026-11-13 $2.8 – $9.61
Market cap
$7.96M
Volume
35.4K (1.7× avg)
3-mo avg 20.7K
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LFWD - Filings & News (Page 3)

LFWD
Feb 09, 2026, 4:26 PM EST
Filing Type: DEFM14A
Importance Score:
9
Price at Filing: $0.5509
Real-time Price: $2.80 info
Change: Reverse Stock Split info
Market Cap: $7.957M info
LFWD
Feb 09, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5602
Real-time Price: $2.80 info
Change: Reverse Stock Split info
Market Cap: $7.957M info
LFWD
Jan 28, 2026, 5:08 PM EST
Filing Type: PREM14A
Importance Score:
9
Price at Filing: $0.660
Real-time Price: $2.80 info
Change: Reverse Stock Split info
Market Cap: $7.957M info
LFWD
Jan 28, 2026, 4:14 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.652
Real-time Price: $2.80 info
Change: Reverse Stock Split info
Market Cap: $7.957M info
LFWD
Jan 13, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.723
Real-time Price: $2.80 info
Change: Reverse Stock Split info
Market Cap: $7.957M info
LFWD
Jan 06, 2026, 4:16 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6384
Real-time Price: $2.80 info
Change: Reverse Stock Split info
Market Cap: $7.957M info
LFWD
Jan 02, 2026, 4:16 PM EST
Filing Type: S-3/A
Importance Score:
9
Price at Filing: $0.6235
Real-time Price: $2.80 info
Change: Reverse Stock Split info
Market Cap: $7.957M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets